



# Prosus Ventures Leads Mevo's New R\$95 Million Financing

Client News

March 25, 2026

Gunderson Dettmer represented [Prosus Ventures](#) as the lead investor in the R\$95 million financing of Mevo, a Brazil-based startup specializing in digital prescriptions for medications and tests.

The company will use the new funding to expand its team and accelerate growth to reach more patients and providers.

“Over the past 18 months, we’ve delivered on the business plan agreed upon with the shareholders, doubling all of the company’s numbers,” said Pedro Dias, Mevo co-founder and CEO, [in a Brazil Journal article profiling the transaction](#). “This funding round reinforces our strategy.”

The Gunderson deal team was led by Christel Moreno and included Eduarda Tavares.

[See more Gunderson work with Prosus Ventures.](#)

Companies

[Prosus Ventures](#)

[Mevo](#)

Related People





Christel H. Moreno  
PARTNER  
P +1 212 430 3139



Eduarda N. Tavares  
ASSOCIATE  
P +1 646 490 9095

## Related Services

- Fund Investments in Companies
- Late-Stage Company
- Latin America
- Private & Public Companies
- Seed, Venture and Growth Financings

## Featured Insights

### EVENTS

The Nuts and Bolts of an IPO

### CLIENT NEWS

UnblockPay Raises \$4.5 Million Seed

CLIENT NEWS

Kleiner Perkins Announces New Funds Totaling \$3.5 Billion

INSIGHTS

Cure Interviews Brett Pletcher in “The Legal Playbook for Building a Biotech Company, From Formation to Financing”

CLIENT NEWS

XBOW Announces \$120 Million Series C, Reaches Unicorn Status

INSIGHTS

Client Insight: California DFPI Suspends Implementation and Enforcement of Diversity Reporting Law

EVENTS

Post-IPO: Engaging Shareholders with Confidence and Credibility

FIRM NEWS

Associates Recognize Gunderson Dettmer as Top Performer for AI Integration and Associate Experience in Chambers Satisfaction Survey

INSIGHTS

Client Insight: Quarterly Employment Law Update — Winter 2026

CLIENT NEWS

Kaszek Ventures Co-Leads Azos R\$125 Million Series C

CLIENT NEWS

Sunday Robotics Raises \$165 Million Series B at \$1.15 Billion Valuation

INSIGHTS

Cure Interviews Brett Pletcher in “Technology Transfer in Biotech and Pharma and the Process of Scaling New Medicines”